High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A

Oncogene

Volumn 33, Issue 44, 2013, Pages 5151-5162

  Nehil, M ^a   Paquette, J ^b   Tokuyasu, T ^b   Mccormick, F ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chromatin; HMGB1; metastasis; migration; SEMA3A

Indexed keywords

EID: 84887051227     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.459     Document Type: Article

References (34)

1. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836-2848.
2. Volp K, Brezniceanu ML, Bosser S, Brabletz T, Kirchner T, Gottel D et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006; 55: 234-242.
3. Maeda S, Hikiba Y, Shibata W, Ohmae T, Yanai A, Ogura K et al. Essential roles of high-mobility group box1 in the development of murine colitis and colitisassociated cancer. Biochem Biophys Res Commun 2007; 360: 394-400.
4. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446-452.
5. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216: 167-175.
6. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005; 64: 92-100.
7. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991-2998.
8. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S et al. HMGB 1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003; 17: 1295-1297.
9. Malarkey CS, Churchill ME. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci 2012; 37: 553-562.
10. Joshi SR, Sarpong YC, Peterson RC, Scovell WM. Nucleosome dynamics: HMGB1 relaxes canonical nucleosome structure to facilitate estrogen receptor binding. Nucleic Acids Res 2012; 40: 10161-10171.
11. Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22: 276-280.
12. Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003; 302: 421-426.
13. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998; 12: 462-472.
14. Ge H, Roeder RG. The high mobility group protein HMG1 can reversibly inhibit class II gene transcription by interaction with the TATA-binding protein. J Biol Chem 1994; 269: 17136-17140.
15. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-99.
16. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGEamphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
17. Liang X, Chavez AR, Schapiro NE, Loughran P, Thorne SH, Amoscato AA et al. Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 2009; 86: 599-607.
18. Dave SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86: 633-643.
19. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-285.
20. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006; 5: 2606-2612.
21. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010; 136: 677-684.
22. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
23. Lin Q, Yang XP, Fang D, Ren X, Zhou H, Fang J et al. High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis. Arterioscler Thromb Vasc Biol 2011; 31: 1024-1032.
24. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008; 8: 632-645.
25. Staton CA, Shaw LA, Valluru M, Hoh L, Koay I, Cross SS et al. Expression of class 3 semaphorins and their receptors in human breast neoplasia. Histopathology 2011; 59: 274-282.
26. Casazza A, Fu X, Johansson I, Capparuccia L, Andersson F, Giustacchini A et al. Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol 2011; 31: 741-749.
27. Schmidt EF, Strittmatter SM. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007; 600: 1-11.
28. Schmidt EF, Shim SO, Strittmatter SM. Release of MICAL autoinhibition by semaphorin-plexin signaling promotes interaction with collapsin response mediator protein. J Neurosci 2008; 28: 2287-2297.
29. Ranzato E, Patrone M, Pedrazzi M, Burlando B. Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation. Cell Biochem Biophys 2010; 57: 9-17.
30. McCauley MJ, Zimmerman J, Maher 3rd LJ, Williams MC. HMGB binding to DNA: single and double box motifs. J Mol Biol 2007; 374: 993-1004.
31. El Gazzar M, Yoza BK, Chen X, Garcia BA, Young NL, McCall CE. Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol Cell Biol 2009; 29: 1959-1971.
32. Sapojnikova N, Maman J, Myers FA, Thorne AW, Vorobyev VI, Crane-Robinson C. Biochemical observation of the rapid mobility of nuclear HMGB1. Biochim Biophys Acta 2005; 1729: 57-63.
33. Paquette J, Tokuyasu T. EGAN: exploratory gene association networks. Bioinformatics 2010; 26: 285-286.
34. Szak ST, Mays D, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 2001; 21: 3375-3386.